Dominant negative ligand chimeric antigen receptor systems
OwnerDaniel J. Monticelloinventor
Life of this patent
Estimating the term…
Abstract
The invention provides modified T-cell receptors referred to herein as “dominant negative ligand-chimeric antigen receptors” (DNL-CARS). The present invention also provides T-cells expressing DNL-CARs such T cells also referred to herein as “DNL-CAR-expressing T cells” or “DNL-CAR T cells. Also provided are “tagged-DNL/CAR-T systems” that direct CAR-T cells to tumor cells previously complexed to the DNL-Tag fusion. Also provided are tagged-DNL-antigen fusion proteins wherein the antigen portion of the fusion proteins recruits the patient's own immune system to neutralize cells tagged with the tagged DNL portion of the fusion protein.
Claims26
A dominant-negative ligand chimeric antigen receptor (DNL-CAR) comprising an intracellular activation domain, an optional costimulatory molecule domain, a transmembrane domain, an extracellular domain, and an optional linker between the transmembrane domain and the extracellular domain, wherein the extracellular domain comprises a dominant-negative ligand (DNL).
16-27. (canceled)
A fusion protein comprising a tagged-DNL fused to an antigen wherein the antigen promotes a non-life-threatening immune response in a patient.
Dependencies are inferred from the claim text.